NC-NOVAQUEST-CAPITAL
20.5.2021 12:32:11 CEST | Business Wire | Press release
Argenta Limited (“Argenta”), the only global contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in animal health, and NovaQuest Capital Management (“NovaQuest”) announced today a $30 million product financing agreement for the development of several innovative veterinary pharmaceuticals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005132/en/
The collaboration leverages NovaQuest’s capital and expertise, and Argenta’s knowledge and know-how in research and development activities that advance animal health.
“The capital investment from NovaQuest accelerates Argenta’s strategy of providing innovative solutions and Molecule to Market services through global partnerships. We are delighted by the collaboration with NovaQuest and we look forward to strengthening our partnership through additional programs in the future,” said Ben Russell, CEO of Argenta.
Argenta will conduct the R&D activities from its locations in the United States and New Zealand and will use proprietary drug delivery technologies to develop what are expected to be the next generation of veterinary pharmaceutical products. Argenta and NovaQuest will look for commercialization partners as the project progresses.
“This is an historic milestone for Argenta and instrumental in advancing our commitment to deliver innovation to the animal health industry. I am excited to leverage our product development expertise, IP and technology to accelerate some of the many options available,” commented Edward McGruder, Global head of Research, Development and Innovation at Argenta.
For NovaQuest, a premier biopharma and life sciences investment firm with extensive experience in human health product financing, this represents their first expansion into a collaboration of this nature within the animal health industry.
“We are excited to enter into this collaboration with Argenta, a trusted global leader in the animal health industry. With this investment we expand NovaQuest’s commitment to funding innovation in animal health across a wide range of companies and products,” said Jonathan Tunnicliffe, Chief Investment Officer of NovaQuest.
“NovaQuest’s commitment to bringing innovation to the animal health industry, combined with Argenta’s unparalleled end-to-end development capabilities and expertise make this a truly exciting collaboration,” said Brian Axe, Managing Director at NovaQuest .
Both companies are eager to start this product development journey to help accelerate innovation in the animal health industry.
Wyrick Robbins Yates & Ponton LLP acted as legal counsel to NovaQuest.
About NovaQuest
Founded by a team of accomplished industry professionals who began working together in 2000, NovaQuest Capital Management is a premier biopharma and life sciences investment firm. NovaQuest pioneered a Product Finance solution for the industry, providing at-risk, nondilutive funding that enables partner companies to advance pivotal clinical trials, launch new brands, license products, and acquire accretive products or companies. NovaQuest has invested in scores of biopharmaceutical assets across therapeutic areas with a clinical success rate higher than the industry average. Currently managing more than $2.2 billion in capital, NovaQuest is actively investing from the $1.2 billion Pharma Opportunities Fund V, evaluating global opportunities with financing needs that range from $30-100 million. Leveraging the core platform, NovaQuest is expanding its strategy to bring much needed capital to the animal health industry. NovaQuest is actively evaluating and investing in opportunities across animal segments and geographies. For more information, please visit www.novaquest.com
About Argenta
Argenta is the only combined global contract research organization (CRO) and contract development and manufacturing organization (CDMO) dedicated to animal health. Founded in 2006 in New Zealand, Argenta’s talented, diverse and committed employees work on a daily basis to deliver excellence in animal health to customers around the world. With research and GMP manufacturing operations in New Zealand, the United States and the United Kingdom, Argenta operates ‘from Molecule to Market’ in partnership with its customers to support their R&D, regulatory, clinical research and manufacturing needs along the veterinary product development journey. For more information about Argenta, please visit www.argentaglobal.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005132/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand31.3.2026 16:00:00 CEST | Press release
Regulatory milestone opens heart health growth opportunities for food and beverage manufacturers IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330523416/en/ First heart health claim approved for soy protein in Australia and New Zealand. “For decades, IFF has invested in the science behind soy protein and its role in supporting cardiovascular health,” said Tony Andrew, vice president of protein solutions for IFF Food Ingredients. “This approved claim validates years of rigorous research and collaboration. With our deep expertise in ing
Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care31.3.2026 15:26:00 CEST | Press release
Sub-Q Bionics, a medical device company developing next-generation solutions to improve care for patients living with lymphedema, today announced the successful close of its $1.5 million pre-seed funding round. The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds. The funding will enable Sub-Q Bionics to continue to develop its novel bionic lymph node technology designed to transform how lymphedema is managed, based on scientific innovations from the Weizmann Institute and Shamir Medical Center. The system aims to provide a solution to manage fluid with a subcutaneous implant that will allow patients freedom of movement, automatic fluid management and reduction of symptoms such as pain and swelling. Lymphedema affects millions of patients worldwide, especially breast cancer survivors, and remains significantly under
HTEC Achieves SOC 2 Type II Attestation, Reinforcing Commitment to Client Trust31.3.2026 15:25:00 CEST | Press release
HTECtoday announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331132225/en/ HTEC today announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. For clients, this means working with a technology partner whose practices are standardized, consistently executed, and independently verified over time. It reflects a level of operational maturity where security, reliability, and data protection are built into every engagement. Achieving this standard required coordinated effort across the entire organization. Compliance, engineering, delivery, security, IT, legal, and people t
Impartner Redefines Partner Marketing Automation with Full Automation, AdTech and AI to Drive Measurable Revenue31.3.2026 15:00:00 CEST | Press release
New automation and AI capabilities connect partner campaigns and engagement directly to pipeline and revenue outcomes. Impartner, the world’s leading partner revenue orchestration platform, today announced a major advancement that unifies partner marketing automation within the platform, powered by full automation, AdTech and AI to turn partner marketing into measurable revenue. As partner ecosystems expand across regions, marketplaces and multi-tier models, marketing execution has often remained fragmented. Impartner eliminates those gaps by unifying recruitment, enablement, campaign automation and performance tracking within a single operational system, making partner demand generation and marketing fully operational, measurable, and scalable across all partner interactions. “What makes partner marketing successful is not content distribution, it’s execution, scale and measurable pipeline and revenue,” said Emile van de Klok, Senior Director of Channel Marketing Solutions at Impartne
Boomi Named a Leader in IDC MarketScape for Worldwide API Management 202631.3.2026 15:00:00 CEST | Press release
Boomi™, the data activation company, today announced it has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment, which evaluates vendors based on their capabilities and strategies for delivering API management solutions (APIM) in an increasingly AI-driven, hybrid enterprise landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331354139/en/ Boomi Named a Leader in IDC MarketScape for Worldwide API Management 2026 As enterprises accelerate adoption of agentic AI and hybrid architectures, the need to govern and scale APIs across increasingly complex environments has become a strategic priority. APIs are central to enabling secure, reusable, and agent-ready access to applications and data. Boomi’s API management solution, with an enterprise-grade gateway and advanced federation capabilities, enables organizations to design, secure, and manage APIs seamlessly across distributed runt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom